Thursday, July 9, 2026

Patent intelligence · US

US 8058268

Neuroprotective agents for the prevention and treatment of neurodegenerative diseases

granted A61KA61K31/167A61K31/34A61K31/4406
Status granted
Linked drugs 2
Pipeline programs 6
Years to expiry 5
Applicant portfolio 26
Patent details — US 8058268
Jurisdiction
US
Status
granted
Grant date
Nov 15, 2011
Expiration
Nov 10, 2031
Claims
6
CPC classes
A61K, A61K31/167, A61K31/34, A61K31/4406
View on Google Patents ↗

Quick answer

US 8058268 (Neuroprotective agents for the prevention and treatment of neurodegenerative diseases) is held by Lixte Biotechnology, Inc.. Status: granted. Granted Nov 15, 2011. Expires Nov 10, 2031 (5 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
6
CPC classes
A61K, A61K31/167, A61K31/34, A61K31/4406, A61K31/445, A61K31/4525

More from Lixte Biotechnology, Inc.

Related pharmaceutical patents in our USPTO index.

  1. US 12343342

    Methods for treating soft tissue sarcoma

    Lixte Biotechnology, Inc. · Expires Jun 26, 2045

    granted
  2. US 11931354

    Formulations of oxabicycloheptanes and oxabicycloheptenes

    Lixte Biotechnology, Inc. · Expires Mar 14, 2044

    granted
  3. US 11866444

    Oxabicycloheptane prodrugs

    Lixte Biotechnology, Inc. · Expires Jan 4, 2044

    granted
  4. US 11236102

    Oxabicycloheptane prodrugs

    Lixte Biotechnology, Inc. · Expires Jan 27, 2042

    granted
  5. US 10668062

    Oxabicycloheptanes and oxabicycloheptenes for the treatment of diabetes

    Lixte Biotechnology, Inc. · Expires May 28, 2040

    granted
  6. US 10618908

    Oxabicycloheptane prodrugs

    Lixte Biotechnology, Inc. · Expires Apr 9, 2040

    granted
  7. US 10532050

    Formulations of oxabicycloheptanes and oxabicycloheptenes

    Lixte Biotechnology, Inc. · Expires Jan 9, 2040

    granted
  8. US 10434100

    Protein phosphatase 2A inhibitors for treating myelodysplastic syndromes

    Lixte Biotechnology, Inc. · Expires Oct 3, 2039

    granted

Frequently asked questions

What is US patent 8058268?

US 8058268 (Neuroprotective agents for the prevention and treatment of neurodegenerative diseases) is held by Lixte Biotechnology, Inc.. Status: granted. Granted Nov 15, 2011. Expires Nov 10, 2031 (5 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 8058268?

Lixte Biotechnology, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 26 pharmaceutical patents for this assignee.

When does US 8058268 expire?

Our index shows an expiration date of Nov 10, 2031 (5 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.